Chimeric Therapeutics Ltd

ASX:CHM (Australia)   Ordinary Shares
A$ 0.01 (-14.29%) Dec 24
At Loss
P/B:
2.00
Market Cap:
A$ 9.45M ($ 5.87M)
Enterprise V:
A$ 9.99M ($ 6.21M)
Volume:
18.31M
Avg Vol (2M):
4.84M
Trade In:
Volume:
18.31M
At Loss

Business Description

Description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.85
Equity-to-Asset 0.16
Debt-to-Equity 1.46
Debt-to-EBITDA -0.3
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 38.95
9-Day RSI 38.35
14-Day RSI 37.74
6-1 Month Momentum % -50
12-1 Month Momentum % -67.86

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.32
Quick Ratio 0.32
Cash Ratio 0.3

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -36.7
Shareholder Yield % -111.56

Profitability Rank

Name Current Vs Industry Vs History
ROE % -170.91
ROA % -58.43
ROIC % -128.01
ROC (Joel Greenblatt) % -8198.21
ROCE % -124.56

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 2
EV-to-EBIT -0.82
EV-to-Forward-EBIT -0.86
EV-to-EBITDA -0.82
EV-to-Forward-EBITDA -0.71
EV-to-FCF -1.33
Earnings Yield (Greenblatt) % -121.95
FCF Yield % -79.76

Financials

ASX:CHM's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Chimeric Therapeutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$)
EPS (TTM) (A$) -0.018
Beta 2.01
Volatility % 68.21
14-Day RSI 37.74
14-Day ATR (A$) 0.001085
20-Day SMA (A$) 0.00755
12-1 Month Momentum % -67.86
52-Week Range (A$) 0.006 - 0.043
Shares Outstanding (Mil) 1,575.15

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Chimeric Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Chimeric Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Chimeric Therapeutics Ltd Frequently Asked Questions

What is Chimeric Therapeutics Ltd(ASX:CHM)'s stock price today?
The current price of ASX:CHM is A$0.01. The 52 week high of ASX:CHM is A$0.04 and 52 week low is A$0.01.
When is next earnings date of Chimeric Therapeutics Ltd(ASX:CHM)?
The next earnings date of Chimeric Therapeutics Ltd(ASX:CHM) is .
Does Chimeric Therapeutics Ltd(ASX:CHM) pay dividends? If so, how much?
Chimeric Therapeutics Ltd(ASX:CHM) does not pay dividend.

Press Release

Subject Date
No Press Release